Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 9.


Clark, Richard E ORCID: 0000-0002-1261-3299, Apperley, Jane F, Copland, Mhairi and Cicconi, Silvia
(2021) Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. BLOOD ADVANCES, 5 (4). pp. 1102-1109.


Kinstrie, Ross, Horne, Gillian A, Morrison, Heather, Irvine, David, Munje, Chinmay, Castaneda, Eduardo Gomez, Moka, Hothri A, Dunn, Karen, Cassels, Jennifer E, Parry, Narissa
et al (show 6 more authors) (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. LEUKEMIA, 34 (6). pp. 1613-1625.


Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios ORCID: 0000-0001-5181-6817, Apperley, Jane F, Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L, de lavallade, Hugues, O'Brien, Stephen G, Coffey, Tony
et al (show 2 more authors) (2017) De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. The Lancet Haematology, 4 (7). E310-E316.


Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios, Apperley, Jane F, Milojkovic, Dragana, Rothwell, Katherine, Pocock, Christopher, Byrne, Jennifer, de lavallade, Hugues, Osborne, Wendy, Robinson, Lisa
et al (show 4 more authors) (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology, 6 (7). E375-E383.


Kinstrie, Ross, Karamitros, Dimitris, Goardon, Nicolas, Morrison, Heather, Hamblin, Mike, Robinson, Lisa, Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi and Vyas, Paresh
(2016) Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. BLOOD ADVANCES, 1 (3). pp. 160-169.


Copland, Mhairi, Slade, Daniel, McIlroy, Graham, Horne, Gillian, Byrne, Jenny L, Rothwell, Kate, Brock, Kristian, De Lavallade, Hugues, Craddock, Charles, Clark, Richard E ORCID: 0000-0002-1261-3299
et al (show 5 more authors) (2022) Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. LANCET HAEMATOLOGY, 9 (2). E121-E132.


Love, Sharon B, Cafferty, Fay, Snowdon, Claire, Carty, Karen, Savage, Joshua, Pallmann, Philip, McParland, Lucy, Brown, Louise, Masters, Lindsey, Schiavone, Francesca
et al (show 26 more authors) (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23 (1). p. 757.


Dennis, Mike, Thomas, Ian F, Ariti, Cono, Upton, Laura, Burnett, Alan K, Gilkes, Amanda, Radia, Rohini, Hemmaway, Claire, Mehta, Priyanka, Knapper, Steven
et al (show 5 more authors) (2021) Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. BLOOD ADVANCES, 5 (24). pp. 5621-5625.


Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono, Severinsen, Marianne T, Hemmaway, Claire, Greaves, Paul, Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi
et al (show 1 more authors) (2021) A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. BRITISH JOURNAL OF HAEMATOLOGY, 194 (2). pp. 298-308.

This list was generated on Sat Feb 17 02:29:21 2024 GMT.